Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

(2015) Kellee M. Miller et al.   DIABETES CARE

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

(2015) Mark R. Rigby et al.   JOURNAL OF CLINICAL INVESTIGATION

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis

(2014) F. D'Addio et al.   DIABETES

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

(2014) Michael J. Haller et al.   JOURNAL OF CLINICAL INVESTIGATION

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment

(2013) Tihamer Orban et al.   DIABETES CARE

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

(2013) Stephen E Gitelman et al.   Lancet Diabetes & Endocrinology

Potent Induction Immunotherapy Promotes Long-Term Insulin Independence After Islet Transplantation in Type 1 Diabetes

(2012) M. D. Bellin et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Autologous Hematopoietic Stem Cell Transplantation Modulates Immunocompetent Cells and Improves β-Cell Function in Chinese Patients with New Onset of Type 1 Diabetes

(2012) Lirong Li et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I

(2010) E Snarski et al.   BONE MARROW TRANSPLANTATION

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus

(2009) Carlos E. B. Couri   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE